万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300482 万孚生物

已收盘 12-26 15:00:00

{"stockData":{"symbol":"300482","market":"SZ","secType":"STK","nameCN":"万孚生物","latestPrice":19.75,"timestamp":1766732631000,"preClose":19.79,"halted":0,"volume":3150018,"delay":0,"changeRate":-0.002,"floatShares":430000000,"shares":468000000,"eps":0.5543,"marketStatus":"已收盘","change":-0.04,"latestTime":"12-26 15:00:00","open":19.84,"high":19.86,"low":19.71,"amount":62324900,"amplitude":0.0076,"askPrice":19.76,"askSize":116,"bidPrice":19.75,"bidSize":415,"shortable":0,"etf":0,"ttmEps":0.5543,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":5,"adr":0,"adjPreClose":19.79,"symbolType":"stock","openAndCloseTimeList":[[1766712600000,1766719800000],[1766725200000,1766732400000]],"highLimit":21.77,"lowLimit":17.81,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":468084872,"isCdr":false,"pbRate":1.72,"roa":"--","peRate":35.630525,"roe":"2.47%","epsLYR":1.21,"committee":0.688889,"marketValue":9245000000,"turnoverRate":0.0073,"status":1,"floatMarketCap":8500000000},"requestUrl":"/m/hq/s/300482","defaultTab":"news","newsList":[{"id":"2594825564","title":"股市必读：万孚生物（300482）12月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2594825564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594825564?lang=zh_cn&edition=full","pubTime":"2025-12-26 02:46","pubTimestamp":1766688371,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，万孚生物报收于19.79元，下跌0.3%，换手率0.67%，成交量2.88万手，成交额5695.14万元。当日关注点来自交易信息汇总：12月25日主力资金净流出789.17万元，散户资金净流入1278.98万元。来自公司公告汇总：万孚生物获国家药监局批准两项医疗器械注册证，涉及全自动核酸检测系统及多联检测试剂盒。试剂盒用于体外定性检测人口咽拭子样本中的腺病毒、肺炎支原体和副流感病毒核酸。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600000895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300482","BK0197"],"gpt_icon":0},{"id":"2594233053","title":"万孚生物：公司目前无海南子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2594233053","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594233053?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:57","pubTimestamp":1766653030,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物(300482)12月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问万孚生物在海南有几家子公司？万孚生物回复：尊敬的投资者您好，公司目前无海南子公司，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500024733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300482","BK0046"],"gpt_icon":0},{"id":"2593107500","title":"万孚生物：已建立稳定的供应链体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2593107500","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593107500?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:54","pubTimestamp":1766390083,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物(300482)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问：面对原材料价格波动的风险，公司是否建立了稳定的供应链体系？是否有通过长期协议、战略储备等方式来保障原材料供应并控制成本？万孚生物回复：尊敬的投资者您好，公司已经建立了稳定的供应链体系，可以通过长期协议、战略储备等方式来保障原材料供应，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200013477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0046","BK0239","BK0197"],"gpt_icon":0},{"id":"2593102374","title":"万孚生物：OTC版流感检测试剂盒市场推广持续进行","url":"https://stock-news.laohu8.com/highlight/detail?id=2593102374","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593102374?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:36","pubTimestamp":1766389000,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物(300482)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司三联检早于九安半年获美FDA认证，且有美国本地量产工厂，当前该产品在美市场渗透率、渠道覆盖（如药店/电商）及销量数据如何？先发优势是否转化为实际营收增量？万孚生物回复：尊敬的投资者您好！感谢您对公司的关注。公司美国 FDA 认证的 OTC 版流感检测试剂盒的市场推广工作在持续进行中，具体对公司营业收入的影响请留意公司定期报告，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200012815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0046","300482"],"gpt_icon":0},{"id":"2590146905","title":"万孚生物（300482）披露债券持有人持有公司可转债比例达到20%，12月11日股价下跌1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590146905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590146905?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:26","pubTimestamp":1765463164,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，万孚生物报收于20.26元，较前一交易日下跌1.94%，最新总市值为94.83亿元。该股当日开盘20.7元，最高20.76元，最低20.25元，成交额达6505.94万元，换手率为0.74%。公司近日发布公告称，广州万孚生物技术股份有限公司于2020年9月1日发行6.00亿元可转换公司债券，债券简称“万孚转债”，代码123064。截至2025年12月11日收盘，优美利投资管理的证券投资基金合计持有“万孚转债”1,230,467张，占可转债发行总量的20.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100042011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300482"],"gpt_icon":0},{"id":"2590515130","title":"万孚生物：AI辅助诊断软件获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590515130?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:48","pubTimestamp":1765457290,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物(300482)12月10日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，能不能通报一下你们公司ai医疗诊断的最新进展？万孚生物回复：尊敬的投资者您好， 公司投资的赛维森科技\"宫颈细胞数字病理图像辅助诊断软件\" 正式获批、这是全国宫颈细胞学领域首张\"Al辅助诊断\"三类产品注册证、标志着\"数字病理+Al辅诊\"模式迈向全新里程碑、 通过AI辅助阅片、显著提升诊断效率与准确性、为患者后续的诊疗提供更精准的方案、感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100038166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300482","BK0239","BK0197"],"gpt_icon":0},{"id":"2590283302","title":"万孚生物：推出一体化呼吸道病原体检测解决方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2590283302","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590283302?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:36","pubTimestamp":1765355771,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物12月10日在投资者关系平台上答复投资者关心的问题。谢谢万孚生物回复：尊敬的投资者您好，面对流感高峰，万孚生物基于当前流感季特点，推出整合试剂、仪器与信息系统的一体化呼吸道病原体检测解决方案，旨在缩短患者等候时间，助力医疗机构平稳应对流感检测高峰。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000023809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0197","BK0239","BK0046"],"gpt_icon":0},{"id":"2590302395","title":"万孚生物：公司2025年9月30日股东人数为42360户","url":"https://stock-news.laohu8.com/highlight/detail?id=2590302395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590302395?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:27","pubTimestamp":1765355243,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物(300482)12月10日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！敬请发布截至今天10月31日公司的股东户数信息万孚生物回复：尊敬的投资者您好，公司2025年9月30日股东人数为42360户，您可将股东身份证明发送至stock@wondfo.com.cn查询最新股东人数。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000022910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300482","BK0239","BK0046"],"gpt_icon":0},{"id":"2588051879","title":"万孚生物（300482）披露取得产品注册证，12月02日股价下跌1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588051879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588051879?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:32","pubTimestamp":1764685953,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，万孚生物报收于20.92元，较前一交易日下跌1.27%，最新总市值为97.92亿元。该股当日开盘21.12元，最高21.22元，最低20.91元，成交额达6031.79万元，换手率为0.67%。产品注册证有效期至2030年11月3日，对公司发展具有正面影响，但目前尚无法预测其对未来营业收入的具体影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200040125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0046","300482"],"gpt_icon":0},{"id":"2585498521","title":"万孚生物（300482）披露回购公司股份实施结果暨股份变动公告，11月24日股价上涨0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498521","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585498521?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:28","pubTimestamp":1763994485,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，万孚生物报收于20.82元，较前一交易日上涨0.68%，最新总市值为97.46亿元。公司近日发布公告称，广州万孚生物技术股份有限公司于2025年9月23日召开董事会，审议通过回购股份方案，拟用于员工持股计划和股权激励。回购股份将用于员工持股计划或股权激励，若36个月内未使用则注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0046","BK0239","BK0197"],"gpt_icon":0},{"id":"2584194131","title":"万孚生物：公司暂无鼻病毒相关检测产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2584194131","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584194131?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:37","pubTimestamp":1763555820,"startTime":"0","endTime":"0","summary":"证券日报网讯万孚生物11月19日在互动平台回答投资者提问时表示，公司暂无鼻病毒相关检测产品，面对潜在的流感高峰，万孚生物基于当前流感季特点，推出整合试剂、仪器与信息系统的一体化呼吸道病原体检测解决方案，旨在缩短患者等候时间，助力医疗机构平稳应对流感检测高峰。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-19/doc-infxxwtt3524080.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-19/doc-infxxwtt3524080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0197","BK0046","BK0239","300482"],"gpt_icon":0},{"id":"2583504230","title":"万孚生物（300482）披露部分募投项目重新论证并暂缓实施公告，11月14日股价下跌1.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583504230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583504230?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:20","pubTimestamp":1763130028,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，万孚生物报收于21.96元，较前一交易日下跌1.3%，最新总市值为102.79亿元。该股当日开盘22.1元，最高22.32元，最低21.91元，成交额达1.48亿元，换手率为1.56%。公司近日发布公告称，于2025年11月14日召开董事会，审议通过《关于部分募投项目重新论证并暂缓实施的议案》，决定在项目实施主体、方式、用途及投资规模不变的前提下，对“知识城生产基地建设项目”重新论证并暂缓实施。该事项无需提交股东大会审议，保荐机构无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400041583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300482","BK0046"],"gpt_icon":0},{"id":"2583579428","title":"万孚生物最新公告：决定暂缓实施知识城生产基地建设项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2583579428","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583579428?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:25","pubTimestamp":1763112320,"startTime":"0","endTime":"0","summary":"万孚生物(300482.SZ)公告称，公司拟在募投项目实施主体、实施方式、募集资金用途及投资规模不发生变更的前提下，将“知识城生产基地建设项目”重新论证并暂缓实施。近年来，鉴于公司经营所面临的内外部环境发生较大变化，为避免资源浪费和重复投资，降低企业生产经营成本，提高募集资金使用效率，公司决定暂缓实施该募投项目，并重新论证该项目的投资收益。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400027775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0197","BK0239","BK0046"],"gpt_icon":0},{"id":"2579483992","title":"万孚生物：三季报不受股权激励费用冲回影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2579483992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579483992?lang=zh_cn&edition=full","pubTime":"2025-10-31 08:57","pubTimestamp":1761872234,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物(300482)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司股权激励取消后，请问前期计提的股权激励费用是否在第三季度冲销，这部分预计对净利润贡献多大？万孚生物回复：尊敬的投资者您好！由于近一年以来外部经营环境发生较大变化，在前期股权激励费用的计提时已经考虑到了这一因素。因此，三季报不会受到股权激励费用冲回的影响。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100013221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482","BK0197","BK0239","BK0046"],"gpt_icon":0},{"id":"2579483189","title":"万孚生物：iCubate公允价值为0","url":"https://stock-news.laohu8.com/highlight/detail?id=2579483189","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579483189?lang=zh_cn&edition=full","pubTime":"2025-10-31 08:57","pubTimestamp":1761872234,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物10月30日在投资者关系平台上答复投资者关心的问题。2025年半年报中“重要的非交易性权益工具投资情况”显示，iCubate,Inc.,公司投资成本3384万元，公允价值为0，发生了什么？根据会计准则及相关计量要求，公司将在年末对其公允价值进行规范计量，并在年度报告中予以披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100013225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300482","BK0197"],"gpt_icon":0},{"id":"2579483975","title":"万孚生物：以业务需求为导向参与行业展会","url":"https://stock-news.laohu8.com/highlight/detail?id=2579483975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579483975?lang=zh_cn&edition=full","pubTime":"2025-10-31 08:57","pubTimestamp":1761872233,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物(300482)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问今年为何没有参加广州的CMEF展会？出于什么的考虑？谢谢万孚生物回复：尊敬的投资者您好！感谢您对公司参展动态的关注。公司一贯秉持 “以业务需求为导向” 的原则参与行业展会，核心目标是通过精准参展实现资源效益最大化。公司会结合展会同期的业务优先级、市场推广重点及资源调配计划来进行综合判断，后续公司将持续关注各类优质展会资源，适时参与以支撑业务发展。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100013220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300482","BK0239","BK0046"],"gpt_icon":0},{"id":"2579906135","title":"万孚生物：依托九大技术平台构建完善产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2579906135","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579906135?lang=zh_cn&edition=full","pubTime":"2025-10-29 20:53","pubTimestamp":1761742410,"startTime":"0","endTime":"0","summary":"证券之星消息，万孚生物10月29日在投资者关系平台上答复投资者关心的问题。公司的初心是，让生命不再等待。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900042287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300482","BK0046"],"gpt_icon":0},{"id":"2578674107","title":"万孚生物（300482）2025年三季报简析：净利润同比下降69.32%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2578674107","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578674107?lang=zh_cn&edition=full","pubTime":"2025-10-28 06:09","pubTimestamp":1761602965,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期万孚生物发布2025年三季报。截至本报告期末，公司营业总收入16.9亿元，同比下降22.52%，归母净利润1.34亿元，同比下降69.32%。按单季度数据看，第三季度营业总收入4.45亿元，同比下降26.66%，第三季度归母净利润-5545.91万元，同比下降169.21%。本报告期万孚生物三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达32.96%。去年的净利率为18.44%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800006622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300482"],"gpt_icon":0},{"id":"2578663980","title":"万孚生物(300482)9月30日股东户数4.24万户，较上期减少5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578663980","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578663980?lang=zh_cn&edition=full","pubTime":"2025-10-26 17:17","pubTimestamp":1761470251,"startTime":"0","endTime":"0","summary":"证券之星消息，近日万孚生物披露，截至2025年9月30日公司股东户数为4.24万户，较6月30日减少2507.0户，减幅为5.59%。在医疗器械行业个股中，万孚生物股东户数高于行业平均水平，截至9月30日，医疗器械行业平均股东户数为2.14万户。从股价来看，2025年6月30日至2025年9月30日，万孚生物区间跌幅为0.28%，在此期间股东户数减少2507.0户，减幅为5.59%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600009757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300482","BK0239","BK0197"],"gpt_icon":0},{"id":"2578636146","title":"万孚生物(300482.SZ)发布前三季度业绩，归母净利润1.34亿元，下降69.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578636146","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578636146?lang=zh_cn&edition=full","pubTime":"2025-10-26 16:58","pubTimestamp":1761469118,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万孚生物(300482.SZ)发布2025年三季度报告，该公司前三季度营业收入为16.9亿元，同比减少22.52%。归属于上市公司股东的净利润为1.34亿元，同比减少69.32%。归属于上市公司股东的扣除非经常性损益的净利润为8264.16万元，同比减少78.67%。基本每股收益为0.28元。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"万孚生物(300482.SZ)发布前三季度业绩，归母净利润1.34亿元，下降69.32%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300482"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766832615045,"stockEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":-0.0559},{"period":"3month","weight":-0.0697},{"period":"6month","weight":-0.0649},{"period":"1year","weight":-0.1337},{"period":"ytd","weight":-0.102}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州万孚生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42360人(较上一季度减少5.59%)","perCapita":"10160股","listingDate":"2015-06-30","address":"广东省广州市黄埔区科学城荔枝山路8号","registeredCapital":"46808万元","survey":"　　广州万孚生物技术股份有限公司的主营业务是快速诊断试剂及配套仪器的研发、生产智造、营销及服务。公司的主要产品是妊娠及优生优育检测、传染病检测、毒品(药物滥用)检测、慢性疾病检测。公司作为中国POCT领域的龙头企业公司先后荣获国家火炬计划重点高新技术企业、国家生物工程高技术产业化示范基地、国家知识产权优势企业、世界海关组织AEO高级认证企业、国家认定企业技术中心、博士后科研工作站、国家知识产权示范企业、广东省第一批制造业单项冠军企业等资质。","listedPrice":16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万孚生物(300482)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万孚生物,300482,万孚生物股票,万孚生物股票老虎,万孚生物股票老虎国际,万孚生物行情,万孚生物股票行情,万孚生物股价,万孚生物股市,万孚生物股票价格,万孚生物股票交易,万孚生物股票购买,万孚生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万孚生物(300482)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万孚生物(300482)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}